aibioX4 Pharmaceuticals replaces loan with up to $150 million K2 facility
Tickers XFOR
The first $80 million tranche repaid the prior loan in full, including $75 million of principal.
Key facts
- Company
- X4 Pharmaceuticals, Inc. (NASDAQ: XFOR)
- News type
- Debt Financing
- Primary source
- X4 Pharmaceuticals, Inc. (2026-10-08)
The facility and the repayment
X4 Pharmaceuticals said on October 8, 2026, that it entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures LLC. The first tranche of $80 million funded at closing. X4 used it to repay in full all obligations under its prior loan and security agreement, including $75 million of principal, related fees and closing costs.
An additional $70 million may be made available at the company's request, but only with K2 HealthVentures' approval and other conditions. The release says the new facility is larger, has a longer interest-only period and carries a 48-month maturity. The company says the structure "provides additional flexibility on more favorable terms," a claim the release does not quantify.
The release describes K2 HealthVentures as an alternative investment firm and quotes its chief executive, Parag Shah, who calls the deal a long-term financing partnership. It names no placement agent or advisor, no administrative agent and no lender for the prior loan, and it defers loan agreement details to SEC filings.
Conditions and risks the company lists
The company's own forward-looking list shows where the facility can tighten. X4 may not meet the conditions for the additional tranches or win K2 HealthVentures' approval for those draws. It may be unable to comply with covenants, including minimum cash and minimum revenue covenants. The interest-only period may not be extended if first commercial U.S. sales of mavorixafor for chronic neutropenia do not come on the expected timeline. Changes in the prime rate may raise the company's interest expense.
The pipeline and the timeline
X4's main asset is mavorixafor, an oral CXCR4 antagonist sold in the United States as XOLREMDI for WHIM syndrome under accelerated approval. The company is running a global, pivotal phase 3 trial, 4WARD, in chronic neutropenia. The 10-K describes it as randomized, double-blind and placebo-controlled, aiming to enroll up to 176 patients, with a 52-week treatment period. The company says it is not actively promoting XOLREMDI in the United States. In 2025 it carried out two restructuring actions that cut head count by approximately 65%, and its chief executive and chief financial officer stepped down in August 2025.
The timeline has moved. The annual report targeted full enrollment in the third quarter of 2026 and topline data in the second half of 2027. The October release now expects enrollment to be completed by year-end 2026 and topline data in the first half of 2028. The company lists as a risk that the interest-only period may not be extended if first commercial U.S. sales of mavorixafor in chronic neutropenia are not achieved on the anticipated timeline, and the release itself calls that launch potential.
The money
The 10-K shows revenue of $6.5 million for 2025, up from $2.6 million for 2024. Research and development expense was $72.7 million in 2025, against $81.6 million in 2024. The net loss widened to $79.2 million in 2025 from $37.5 million in 2024. Cash used in operations fell to $85.6 million in 2025 from $130.9 million in 2024.
The company raised $81.0 million net in a private placement in the third quarter of 2025 and $145.6 million net in a public offering in the fourth quarter. It reported $253.0 million in cash, cash equivalents and marketable securities at December 31, 2025. Year-end cash and cash equivalents were $55.7 million for 2024 and $217.0 million for 2025, according to a 10-Q filed August 6, 2026. At June 30, 2026, cash and cash equivalents were $195.1 million.
The balance sheet is stronger than a year earlier, but the net loss is wider and the company now carries a senior secured loan on top of its equity raises. The release says the facility supports corporate and commercial activities, but it does not describe how the additional $70 million would be used or give a cash runway figure.
What comes next
The next checkpoints are enrollment completion by year-end 2026, the 4WARD topline data in the first half of 2028 and the first draw of the additional $70 million, which needs K2 HealthVentures' approval. The release does not set a date for the additional draw.